Despite the global impact of Covid-19, Johnson & Johnson had another strong year in terms of sales and earnings. While the company’s vaccine may not have lived up to expectations its pharma business managed to perform well. Increased brand marketing expense in the consumer health business was mostly offset by expense leveraging in the pharmaceutical business, resulting in relatively flat selling, marketing, and administrative margins. The management continues to invest at a competitive level in ....
30 May 2022
Johnson & Johnson: Financial & Price Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Johnson & Johnson: Financial & Price Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
Johnson & Johnson (JNJ:NYS), 0 | Johnson & Johnson (0R34:LON), 14,650
- Published:
30 May 2022 -
Author:
Ishan Majumdar -
Pages:
26
Despite the global impact of Covid-19, Johnson & Johnson had another strong year in terms of sales and earnings. While the company’s vaccine may not have lived up to expectations its pharma business managed to perform well. Increased brand marketing expense in the consumer health business was mostly offset by expense leveraging in the pharmaceutical business, resulting in relatively flat selling, marketing, and administrative margins. The management continues to invest at a competitive level in ....